Geneva, Switzerland, May 4th 2015 – EspeRare today announced that the European Medicines Agency (EMA) has granted an Orphan Drug Designation (ODD) for rimeporide, its lead compound for the treatment of Duchenne muscular dystrophy (DMD). DMD is a rare, life-threatening disease affecting boys early in childhood that causes muscle weakness and muscle loss. It is the most common and serious form of paediatric muscular dystrophies.
Find an actor

CES 2019 Las Vegas - Swiss Pavilion08.01.2019

Join the Swiss Pavilion during the Consumer Electronic Show from 8 to 11 January 2019 in Las Vegas, USA.

"Using water molecules to unlock neurons' secrets"

EPFL News : "EPFL researchers have developed a method to observe the electrical activity of neurons by analyzing the...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn